Dade Behring公司获得预测心脏病发作的新技术

Dade Behring公司从美国Cleveland诊所获得如下授权：将髓过氧化物酶自动检测商品化的特定半独有权利。

根据Cleveland诊所进行的研究发现：髓过氧化物酶检测对发病时肌钙蛋白A低水平（通常提示心肌细胞没有死亡）的胸痛患者特别有诊断价值。在这种情况下，髓过氧化物酶水平升高与随后发生的心脏病有联系。因此简单的MPO检测有助于医生鉴别出那些随后可能心脏病发作的患者，从而指导他们在心脏病发作之前开始治疗。

Cleveland诊所的研究人员对急诊室里主诉胸痛的600多位患者的初始髓过氧化物酶水平进行了研究。通过髓过氧化物酶检测以及其它相关实验室风险评估，研究人员把预测患者发病后30天～6个月出现心脏问题的能力，从54%提高至85％。在欧洲完成的一项较大规模的研究证实了这些结果。

Cleveland诊所心血管科主任Eric J. Topol医学博士说：“一项简单的血液检测就能够帮助医生鉴别出存在心脏损害危险的患者是令人兴奋的，我们需要建立肌钙蛋白的检测来改变医学发展现状，髓过氧化物酶检测或许是达到这个目标的途径之一。”

Dade Behring to Develop Cardiac Marker Tests
 
Certain semi-exclusive diagnostic rights for the commercialization of automated diagnostic tests using myeloperoxidase (MPO) have been granted to Dade Behring (Deerfield, IL, USA) by The Cleveland Clinic (OH, USA).

According to research conducted at The Cleveland Clinic, MPO testing may be particularly beneficial in patients with chest pain who exhibit low initial troponin (a) levels, usually an indication that no heart muscle cells have died. In this case, the presence of an elevated MPO level has been linked to risk for subsequent cardiac events. Therefore, a simple MPO blood test has the potential to help doctors identify patients at risk of subsequent heart attack and refer them for treatment prior to the occurrence of heart damage.

Researchers at the Cleveland Clinic investigated initial MPO levels in more than 600 patients in the emergency room complaining of chest pain. By using an MPO blood test in addition to laboratory-based risk assessments, they increased their ability to identify patients who would have heart problems during the next 30 days to six months from 54% to 85%. A larger study in Europe has confirmed these results.

“The potential of a simple blood test to help identify patients at particular risk of heart damage is very exciting,” commented Eric J. Topol, M.D., chairman of The Cleveland Clinic’s department of cardiovascular medicine. “We need to build on the great success of the troponin test in changing medicine, and the MPO test may be a way to do that.”